- $237.48bn
- $280.79bn
- $36.75bn
Brief: Amgen Says Imdelltra Combo Reduced Risk Of Death By 58% In First-Line Lung Cancer
Corrected: Amgen drug combined with immunotherapy extends survival in lung cancer trial
US RESEARCH ROUNDUP- Amgen, Lockheed Martin, Norfolk Southern
Eli Lilly hits record high as healthcare stocks rally
AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial
Press Digest: Wall Street Journal - October 20
Mattel appoints Amgen's Peter Griffith as CFO, succeeding Paul Ruh
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Healthcare stocks rally as investors seek safety amid tech debt worries
Factbox: Global healthcare companies invest billions to boost US presence
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
Amgen's autoimmune drug succeeds in late-stage trial (updated)
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
Amgen rises after autoimmune drug meets late-stage trial goal
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Amgen Says Dazodalibep Meets Primary Endpoint In Phase 3 Sjögren's Disease Trial
Corrected: Amgen's autoimmune drug succeeds in late-stage trial
Roche's obesity drug boosts blood sugar control, drives 15.5% weight loss in mid-stage trial